Cargando…
Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
BACKGROUND: Biosimilar drugs have broadened the treatment options in assisted reproductive technology (ART). Real-world data comparing clinical outcomes of originator follitropin alfa (Gonal-f(®)) with its biosimilars are required to enrich the body of evidence for clinical decision-making on choice...
Autores principales: | Patel, Nayana Hitesh, Patel, Niket H., Patel, Molina Niket, Bhadarka, Harsha K., Vyas, Kairavi Sunilkumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404022/ https://www.ncbi.nlm.nih.gov/pubmed/37547084 http://dx.doi.org/10.4103/jhrs.jhrs_37_23 |
Ejemplares similares
-
Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Publicado: (2023) -
Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars
por: Riccetti, Laura, et al.
Publicado: (2019) -
Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
por: Manzi, Lucio, et al.
Publicado: (2022) -
Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010) -
A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility
por: Gizzo, Salvatore, et al.
Publicado: (2016)